BHC
Bausch Health Companies Inc.
Healthcare · Drug Manufacturers - Specialty & Generic · NYQ
$5.37
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
MODERATE
Data Confidence: 71.4%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$2.0B
Total market value of the company
Trailing P/E
N/A
Forward P/E
1.33
Based on estimated future earnings — lower means cheaper
Rev Growth
+11.7%
Year-over-year revenue change
Profit Margin
-11.5%
How much profit the company keeps from each dollar of revenue
ROE
N/A
Return on equity — how efficiently it uses shareholder money
Analyst Target
$7.50
+40% from current price — median analyst estimate
Recommendation
HOLD
Consensus view from 6 analysts covering this stock
About Bausch Health Companies Inc.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

https://www.bauschhealth.com

Country: Canada Employees: 20,300 Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
0.149
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0117
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.109
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-6.1%
Historical annualised return based on price data
Max Drawdown
-55.8%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
86
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.42
Very low correlation to market moves
52W High
$8.69
38% below the year high
52W Low
$4.41
22% above the year low
Avg Volume
1,822,381
Average daily shares traded — higher means easier to buy and sell
Short Ratio
3.4
Days it would take all short sellers to cover — higher means more crowded
Short % Float
2.0%
Low short interest — limited bearish positioning
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$-3.24
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
N/A
Current Ratio
1.32
Adequate but worth monitoring
Quick Ratio
0.77
Like current ratio but excludes inventory — stricter test
Gross Margin
71.0%
Revenue left after cost of goods — higher means pricing power
Operating Margin
20.6%
Profit from core operations before interest and tax
Free Cash Flow
$1.1B
Positive — the business generates more cash than it spends
Revenue (TTM)
$10.5B
Total revenue over the last 12 months
Net Income
$-1,208,000,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
6
Target High
$9.00
Target Median
$7.50
Target Low
$6.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.